# carricktherapeutics.com

> AI-optimized mirror of carricktherapeutics.com containing 80 pages totalling 31,060 words of clean markdown content, structured data, and semantic HTML. Original source: https://carricktherapeutics.com. Last updated: 2026-07-26T02:27:29.341Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Carrick Therapeutics, Inc.](/content/site-root.html) (94 words)

## Articles & Blog Posts

- [Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (1,069 words)
- [Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/18/carrick-therapeutics-and-the-menarini-group-announce.html): 
Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer
DUBLIN and FLORENCE, Italy, Dec.…... (805 words)
- [Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration.html): 
Collaboration expands Carrick’s clinical-stage Oncology program

DUBLIN, Ireland and BOSTON, July  06, 2023  (GLOBE NEWSWIRE) -- Carrick…... (873 words)
- [Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting.html): 

Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastases  …... (791 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 
BOSTON, Feb.  14, 2024  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (666 words)
- [Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind.html): 
DUBLIN, Ireland and BOSTON, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering…... (396 words)
- [investors/sec-filings/section-16-filings/rss/index.html](/content/investors/sec-filings/section-16-filings/rss/index.html) (40 words)
- [investors/sec-filings/quarterly-reports/rss/index.html](/content/investors/sec-filings/quarterly-reports/rss/index.html) (20 words)
- [investors/news-events/presentations/rss/index.html](/content/investors/news-events/presentations/rss/index.html) (13 words)
- [Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/18/carrick-therapeutics-and-the-menarini-group-announce.html): 
Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer
DUBLIN and FLORENCE, Italy, Dec.…... (776 words)
- [news-media/press-releases/rss/index.html](/content/news-media/press-releases/rss/index.html) (276 words)
- [Corporate Governance :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/index.html) (1,940 words)
- [Board of Directors :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/board-of-directors/index.html) (1,911 words)
- [Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase.html): 

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation  Phase 2…... (969 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 
BOSTON, Dec.  15, 2023  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (541 words)
- [Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in.html): Appoints David Sutherland, CPA, as Vice President of Finance and Controller
BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an…... (422 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 

BOSTON, Sept.  23, 2024  (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and…... (458 words)
- [Management Team :: Carrick Therapeutics, Inc.](/content/investors/company-information/executive-team/index.html) (851 words)
- [investors/news-events/press-releases/rss/index.html](/content/investors/news-events/press-releases/rss/index.html) (294 words)
- [Press Releases :: Carrick Therapeutics, Inc.](/content/investors/news-events/press-releases/index.html) (252 words)
- [Board Diversity :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/board-diversity/index.html) (70 words)
- [investors/sec-filings/annual-reports/rss/index.html](/content/investors/sec-filings/annual-reports/rss/index.html) (20 words)
- [investors/sec-filings/all-sec-filings/rss/index.html](/content/investors/sec-filings/all-sec-filings/rss/index.html) (21 words)
- [Whistleblower Policy :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/whistleblower-policy/index.html) (44 words)
- [Section 16 Filings :: Carrick Therapeutics, Inc.](/content/investors/sec-filings/section-16-filings/index.html) (16 words)
- [Governance Documents :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/governance-documents/index.html) (50 words)
- [Board Committees :: Carrick Therapeutics, Inc.](/content/investors/corporate-governance/board-committees/index.html) (50 words)
- [ESG :: Carrick Therapeutics, Inc.](/content/investors/esg/index.html) (44 words)
- [Annual Reports :: Carrick Therapeutics, Inc.](/content/investors/sec-filings/annual-reports/index.html) (9 words)
- [Quarterly Reports :: Carrick Therapeutics, Inc.](/content/investors/sec-filings/quarterly-reports/index.html) (9 words)
- [SEC Filings :: Carrick Therapeutics, Inc.](/content/investors/sec-filings/index.html) (14 words)
- [All SEC Filings :: Carrick Therapeutics, Inc.](/content/investors/sec-filings/all-sec-filings/index.html) (9 words)
- [Charts :: Carrick Therapeutics, Inc.](/content/investors/stock-data/charts/index.html) (57 words)
- [Historical Data :: Carrick Therapeutics, Inc.](/content/investors/stock-data/historical-data/index.html) (57 words)
- [Quote :: Carrick Therapeutics, Inc.](/content/investors/stock-data/quote/index.html) (57 words)
- [Contacts :: Carrick Therapeutics, Inc.](/content/investors/company-information/contacts/index.html) (44 words)
- [investors/stock-data/index.html](/content/investors/stock-data/index.html) (57 words)
- [Company Information :: Carrick Therapeutics, Inc.](/content/investors/company-information/index.html) (12 words)
- [Financial Results :: Carrick Therapeutics, Inc.](/content/investors/financial-information/financial-results/index.html) (50 words)
- [Financial Information :: Carrick Therapeutics, Inc.](/content/investors/financial-information/index.html) (9 words)
- [FAQ :: Carrick Therapeutics, Inc.](/content/investors/company-information/faq/index.html) (44 words)
- [IR Calendar :: Carrick Therapeutics, Inc.](/content/investors/news-events/ir-calendar/index.html) (11 words)
- [News & Events :: Carrick Therapeutics, Inc.](/content/investors/news-events/index.html) (63 words)
- [Annual Reports & Proxy Statements :: Carrick Therapeutics, Inc.](/content/investors/company-information/annual-reports-proxy-statements/index.html) (50 words)
- [Presentations :: Carrick Therapeutics, Inc.](/content/investors/news-events/presentations/index.html) (57 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/21/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (1,037 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/23/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 
BOSTON, Feb.  14, 2024  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (657 words)
- [Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/19/carrick-therapeutics-announces-clinical-trial-collaboration.html): 
Collaboration expands Carrick’s clinical-stage Oncology program

DUBLIN, Ireland and BOSTON, July  06, 2023  (GLOBE NEWSWIRE) -- Carrick…... (931 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/22/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 
BOSTON, Dec.  15, 2023  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing…... (550 words)
- [Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/24/carrick-therapeutics-establishes-new-headquarters-in.html): Appoints David Sutherland, CPA, as Vice President of Finance and Controller
BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an…... (422 words)
- [Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/20/carrick-therapeutics-announces-u-s-fda-clearance-of-ind.html): 
DUBLIN, Ireland and BOSTON, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering…... (359 words)
- [Email Alerts :: Carrick Therapeutics, Inc.](/content/email-alerts/index.html) (144 words)
- [Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/27/carrick-therapeutics-announces-positive-results-from-phase.html): 

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation  Phase 2…... (967 words)
- [Posters & Publications :: Carrick Therapeutics, Inc.](/content/news-media/posters-publications/index.html) (372 words)
- [Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/26/carrick-therapeutics-announces-new-clinical-data-supporting.html): 

Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastases  …... (782 words)
- [Email Alerts :: Carrick Therapeutics, Inc.](/content/investors/news-events/email-alerts/index.html) (157 words)
- [IR Calendar :: Carrick Therapeutics, Inc.](/content/news-media/ir-calendar/index.html) (23 words)
- [Press Releases :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/index.html) (245 words)
- [news-media/in-the-news/rss/index.html](/content/news-media/in-the-news/rss/index.html) (63 words)
- [In The News :: Carrick Therapeutics, Inc.](/content/news-media/in-the-news/index.html) (36 words)
- [Board of Directors & Observers :: Carrick Therapeutics, Inc.](/content/about/board-of-directors-observers/index.html) (1,910 words)
- [Posters & Publications :: Carrick Therapeutics, Inc.](/content/science/posters-publications/index.html) (368 words)
- [Cookie Policy :: Carrick Therapeutics, Inc.](/content/cookie-policy/index.html) (1,553 words)
- [Privacy Policy :: Carrick Therapeutics, Inc.](/content/privacy-policy/index.html) (1,671 words)
- [CDK7 Inhibitor :: Carrick Therapeutics, Inc.](/content/pipeline/cdk7-inhibitor/index.html) (780 words)
- [Partnering :: Carrick Therapeutics, Inc.](/content/partnering/index.html) (294 words)
- [Management Team :: Carrick Therapeutics, Inc.](/content/about/management-team/index.html) (851 words)
- [Collaborators & Advisors :: Carrick Therapeutics, Inc.](/content/about/advisors-collaborators/index.html) (561 words)
- [Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.](/content/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase.html): 

BOSTON, Sept.  23, 2024  (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and…... (454 words)
- [Science :: Carrick Therapeutics, Inc.](/content/science/index.html) (337 words)
- [CDK12/13 Inhibitor :: Carrick Therapeutics, Inc.](/content/pipeline/cdk1213-inhibitor/index.html) (184 words)
- [Pipeline :: Carrick Therapeutics, Inc.](/content/pipeline/index.html) (121 words)
- [News & Media :: Carrick Therapeutics, Inc.](/content/news-media/index.html) (63 words)
- [Disclaimer :: Carrick Therapeutics, Inc.](/content/disclaimer/index.html) (252 words)
- [CDK7 Biology Schematic :: Carrick Therapeutics, Inc.](/content/science/cdk7-biology-schematic/index.html) (9 words)
- [CDK1213 Biology Schematic :: Carrick Therapeutics, Inc.](/content/science/cdk1213-biology-schematic/index.html) (9 words)
- [Careers :: Carrick Therapeutics, Inc.](/content/careers/index.html) (93 words)

## About Pages

- [About :: Carrick Therapeutics, Inc.](/content/about/index.html) (375 words)
- [Contact :: Carrick Therapeutics, Inc.](/content/contact/index.html) (49 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives